A Phase IIa Study of KHK4563

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions
Uncontrolled and Suspected Eosinophilic Asthma
Interventions
DRUG

KHK4563

every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

DRUG

KHK4563

every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

DRUG

KHK4563

every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

DRUG

Placebo

every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

Trial Locations (29)

Unknown

Nagoya

Toyota-shi

Kamogawa-shi

Fukuoka

Ogaki-shi

Hiroshima

Sapporo

Himeji-shi

Kobe

Sagamihara-shi

Yokohama

Kumamoto

Kyoto

Nagasaki

Kishiwada-shi

Koshigaya-shi

Shizuoka

Itabashi-ku

Shinagawa-ku

Shinjuku-ku

Mizunami-shi

Osakasayama-shi

Oura-gun

Seto-shi

Chungcheongbuk-do

Gwangju

Gyenggi-do

Seoul

Suwon

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT01412736 - A Phase IIa Study of KHK4563 | Biotech Hunter | Biotech Hunter